Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated influenza vaccine NH 2007-2008 formulation · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Study Group 1 | EXPERIMENTAL | Participants aged 18 to 60 years at enrollment |
| Study Group 2 | EXPERIMENTAL | Participants aged 61 years or older at enrollment. |
| Name | Type | Description |
|---|---|---|
| Inactivated influenza vaccine (split virion) NH 2007-2008 formulation | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
It is a split virion inactivated influenza vaccine developed by Sanofi for the 2007-2008 influenza season. It is designed to prevent influenza and related Orthomyxoviridae infections. The formulation was studied in a Phase 2 clinical trial in healthy adult volunteers aged 18 years and older.
It is used for the prevention of influenza and Orthomyxoviridae infections. The vaccine was evaluated in healthy adult volunteers in the United Kingdom. It is an inactivated, split virion vaccine formulation developed for the 2007-2008 influenza season.
Sanofi develops the inactivated influenza vaccine NH 2007-2008 formulation. Sanofi trades under the ticker SNY. The company sponsored the Phase 2 study of this seasonal influenza vaccine candidate.
It is in Phase 2 development. One Phase 2 trial of the vaccine has been completed, and no trials are currently active. The completed study enrolled 130 participants and assessed immunogenicity and safety.
The vaccine was studied in NCT00491257, titled A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine. This Phase 2 trial was completed, enrolled 130 healthy adult volunteers aged 18 years and older, and was conducted in the United Kingdom.